- Home
- ADAP vs NHS Comparison
ADAP vs NHS Comparison
Compare ADAP & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- NHS
- Stock Information
- Founded
- ADAP 2008
- NHS 2003
- Country
- ADAP United Kingdom
- NHS United States
- Employees
- ADAP N/A
- NHS N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- NHS Trusts Except Educational Religious and Charitable
- Sector
- ADAP Health Care
- NHS Finance
- Exchange
- ADAP Nasdaq
- NHS Nasdaq
- Market Cap
- ADAP 212.3M
- NHS 213.4M
- IPO Year
- ADAP 2015
- NHS N/A
- Fundamental
- Price
- ADAP $0.59
- NHS $7.67
- Analyst Decision
- ADAP Strong Buy
- NHS
- Analyst Count
- ADAP 4
- NHS 0
- Target Price
- ADAP $3.16
- NHS N/A
- AVG Volume (30 Days)
- ADAP 2.0M
- NHS 111.8K
- Earning Date
- ADAP 11-13-2024
- NHS 01-01-0001
- Dividend Yield
- ADAP N/A
- NHS 13.44%
- EPS Growth
- ADAP N/A
- NHS N/A
- EPS
- ADAP N/A
- NHS N/A
- Revenue
- ADAP $175,041,000.00
- NHS N/A
- Revenue This Year
- ADAP $180.15
- NHS N/A
- Revenue Next Year
- ADAP N/A
- NHS N/A
- P/E Ratio
- ADAP N/A
- NHS N/A
- Revenue Growth
- ADAP 146.27
- NHS N/A
- 52 Week Low
- ADAP $0.42
- NHS $6.95
- 52 Week High
- ADAP $2.05
- NHS $9.17
- Technical
- Relative Strength Index (RSI)
- ADAP 26.22
- NHS 28.61
- Support Level
- ADAP $0.75
- NHS $7.96
- Resistance Level
- ADAP $0.83
- NHS $8.16
- Average True Range (ATR)
- ADAP 0.07
- NHS 0.15
- MACD
- ADAP -0.01
- NHS -0.02
- Stochastic Oscillator
- ADAP 2.36
- NHS 2.86
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.